Scindeks Asistent Scindeks Asistent
Vol. 75 Br. 12 (2018)

Ukupno preživljavanje bolesnika sa nesitnoćelijskim karcinomom pluća nakon hirurškog lečenja

DOI: 10.2298/VSP161226043L
Olivera Lončarević
Centre for Clinical Pharmacology; Medical Faculty Military Medical Academy, University of Defence, Belgrade, Serbia
Slobodan Aćimović
Military Medical Academy, Pulmonology Clinic, Belgrade, Serbia
Jelena Vuković
Military Medical Academy, Pulmonology Clinic, Belgrade, Serbia
Marko Stojisavljević
Military Medical Academy, Pulmonology Clinic, Belgrade, Serbia
Nebojša Marić
Military Medical Academy, Clinic for Chest Surgery, Belgrade, Serbia
Slobodan Lončarević
Military Medical Academy, Clinic for Maxillofacial Surgery, Belgrade, Serbia
Marina Petrović
Clinical Center „Kragujevac“, Center for Pulmonary Diseases, Kragujevac, Serbia
Ivana Milivojević
Special Hospital for Lung Disease „Ozren“, Sokobanja, Serbia
Gordana Ignjić
PHO Hospital „Sveti vračevi“, Department of Pulmonology, Bijeljina, Bosnia and Herzegovina
Gordana Milić
Military Medical Academy, Pulmonology Clinic, Belgrade, Serbia
Leonida Mirilo
BELhospice – Center for Palliative Care and Palliative Medicine, Belgrade, Serbia
Nemanja Rančić
Military Medical Academy, Centre for Clinical Pharmacology, Belgrade, Serbia
PDF (engleski)

Objavljeno

2021-01-11

Sekcija

Originalni članak

Kako citirati

1.
Lončarević O, Aćimović S, Vuković J, Stojisavljević M, Marić N, Lončarević S, i drugi. Ukupno preživljavanje bolesnika sa nesitnoćelijskim karcinomom pluća nakon hirurškog lečenja. Vojnosanit Pregl [Internet]. 11. Januar 2021. [citirano 20. Septembar 2026.];75(12). Dostupno na: https://test.aseestant.ceon.rs/index.php/vsp/article/view/12787
ACS APA ABNT Chicago Harvard IEEE Vancouver

Preuzimanje za menagere referenci

Endnote/Zotero/Mendeley (RIS) BibTeX

Sažetak

Uvod/Cilj. Karcinom pluća je jedan od najčešćih malignih tumora. Oko 80% karcinoma pluća jeste nesitnoćelijski karcinom pluća (NSCLC). Na osnovu patohistoloških karakteristika, najčešći tipovi NSCLC su skvamocelularni karcinom i adenokarcinom. Cilj studije bio je da se analizira preživ­ljavanje bolesnika sa NSCLC na osnovu njihovog patohistološkog tipa i T – primarni tumor, N – regionalni limfni nodusi, M – udaljene metastaze (TNM) stadijuma koji su lečeni hiruški, a nakon toga prema TNM stadijumu hemio­terapijskim protokolima i/ili radioterapijom. Metode. Izvršena je retrospektivna analiza preživljavanja bolesnika sa NSCLC lečenih u Vojnomedicinskoj akademiji u Beogradu u periodu 2010–2015. Ukupan broj bolesnika je bio 85 (27 žena i 58 muškaraca). Rezultati. Kod bolesnika sa skvamocelularnim karcinomom stopa smrtnosti bila je 19,5% kod ukupno 41 bolesnika, dok je kod bolesnika sa adenokarcinomom stopa smrtnosti bila 43,2% kod ukupno 44 bolesnika. Prosečno ukupno preživljavanje bilo je statistički značajno kraće kod bolesnika sa adenokarcinomom u poređenju sa onima koji su imali skvamocelularni karcinom (1605,2 vs. 1304,8 dana; p = 0.005). S druge strane, prosečno ukupno preživljavanje je bilo statistički značajno kraće kod bolesnika sa adenokarcinomom kod kojih se javio recidiv bolesti u poređenju sa bolesnicima sa skvamocelularnim karcinomom kod kojih se takođe javio recidiv (1212,8 vs. 1835,5 dana; p = 0.032). Zaključak. Adenokarcinom je mnogo agresivniji karcinom u poređenju sa skvamocelularnim karcinomom sa kraćim ukupnim preživljavanjem. Potrebne su dodatne studije kako bi se identifikovali faktori rizika za pojavu recidiva bolesti nakon hiruškog lečenja i kako bi se dodatno objasnila uloga tumorskih markera i tehnika molekularne biologije u progresiji bolesti.

Ključne reči

pluća, nesitnoćelijski karcinom;
adenokarcinom;
karcinom skvamoznih ćelija;
preživljavanje;
recidiv.
DOI: 10.2298/VSP161226043L

Reference

References

American Cancer Society. Cancer facts and figures. 2016. Availa-ble from: http://www.cancer.org/acs/groups/content/@research /do-cuments/document/acspc-047079.pdf

Fenchel K, Sellmann L, Dempke WC. Overall survival in non-small cell lung cancer-what is clinically meaningful? Transl Lung Cancer Res 2016; 5(1): 115–9.

Global Burden of Disease Cancer Collaboration. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, Regional, and National Cancer Incidence, Mortali-ty, Years of Life Lost, Years Lived With Disability, and Disa-bility-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol 2017; 3(4): 524–8.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Can¬cer statistics, 2008. CA Cancer J Clin 2008; 58(2): 71–96.

Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage dis-tri¬bution for patients with non-small cell lung cancer: a Na-tional Cancer Database survey. J Thorac Oncol 2010; 5(1): 29–33.

Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. World Health Organization classification of tumours. Pathol-ogy and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004.

Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Wal-dron W. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesede, MD: National Cancer Insti-tute; 2009. Available from: http://seer.cancer.gov/csr/1975_2009_pops09/

Milašinović G. Nationality guidelines of good clinical practice: Lung cancer. Belgrade: National Expert Commission for the Development and Implementation of Good Clinical Practice Guide; 2012. (Serbian) Available from: http://www.zdravlje.gov.rs/downloads/2011/Decembar/

Vodici/Vodic%20za%20dijagnostikovanje%20i%20lecenje%

karcinoma%20pluca.pdf

Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83(5): 584–94.

Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Van¬steenkiste J, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung can-cer. N Engl J Med 2004; 350(4): 351–60.

Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): A systematic review. Thorax 2001; 56(8): 628–38.

Strand T, Brunsvig PF, Johannessen DC, Sundstrøm S, Wang M, Horn¬slien K, et al. Potentially curative radiotherapy for non-small-cell lung cancer in Norway: A population-based study of survival. Int J Radiat Oncol Biol Phys 2011; 80(1): 133–41.

Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, et al. Radiotherapy alone versus combined chemo-therapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Can¬cer Inst 1991; 83(6): 417–23.

Durm G, Hanna N. Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am 2017; 31(1): 71–81.

Heist RS. First-Line Systemic Therapy for Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am 2017; 31(1): 59–70.

Tam K, Daly M, Kelly K. Treatment of Locally Advanced Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am 2017; 31(1): 45–57.

Chuang JC, Liang Y, Wakelee HA. Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am 2017; 31(1): 31–44.

Park SJ, More S, Murtuza A, Woodward BD, Husain H. New Tar¬gets in Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am 2017; 31(1): 113–29.

Pisters KM, Le Chevalier T. Adjuvant chemotherapy in com-pletely resected non-small-cell lung cancer. J Clin Oncol 2005; 23(14): 3270–8.

Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111(6): 1710–7.

Crinò L, Weder W, van Meerbeeck J, Felip E. ESMO Guidelines Working Group. Early stage and locally advanced (non-me¬ta-static) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v103–15.

Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for ad-van¬ced non-small-cell lung cancer. N Engl J Med 2002; 346(2): 92–8.

Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61(4): 212–36.

Kawase A, Yoshida J, Ishii G, Nakao M, Aokage K, Hishida T, et al. Differences between squamous cell carcinoma and adeno-carcinoma of the lung: Are adenocarcinoma and squamous cell carcinoma prognostically equal. Jpn J Clin Oncol 2012; 42(3): 189–95.

American Cancer Society. Non-small cell lung cancer stages. [cit-ed 2016 May 16]. Available from: http://www.cancer.org/cancer/lungcancer-non-smal¬l-cell/detailedguide/non-small-cell-lung-cancer-survival-rates

Sasaki H, Suzuki A, Tatematsu T, Shitara M, Hikosaki Y, Okuda K, et al. Prognosis of recurrent non-small cell lung cancer fol-lowing complete resection. Med Lett 2014; 7(4): 1300–4.

Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res 2014; 3(4): 242–9.

Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K. Risk factors for tumor recurrence in patients with early-stage (stage I and II) non-small cell lung cancer: Patient selection criteria for adjuvant chemotherapy according to the seventh edition TNM classification. Chest 2011; 140(6): 1494–502.

Shoji F, Haro A, Yoshida T, Ito K, Morodomi Y, Yano T, et al. Prog¬nostic significance of intratumoral blood vessel invasion in pathologic stage IA non-small cell lung cancer. Ann Thorac Surg 2010; 89(3): 864–9.